Zacks Investment Research Lowers Evotec AG (EVTCY) to Hold

Zacks Investment Research downgraded shares of Evotec AG (NASDAQ:EVTCY) from a buy rating to a hold rating in a research report released on Tuesday.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, DZ Bank AG reiterated a sell rating on shares of Evotec AG in a research report on Wednesday, July 12th.

Evotec AG (NASDAQ:EVTCY) last released its earnings results on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.03). The company had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers Evotec AG (EVTCY) to Hold” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply